The largest database of trusted experimental protocols

5 protocols using anti cd57 apc

1

CD8+NKG2D+ Cells Analysis in Tumor

Check if the same lab product or an alternative is used in the 5 most similar protocols
For CD8+NKG2D+ cells analysis, cells were harvested and stained with anti-CD3-FITC (E10472-1633, eBioscience, USA), anti-CD8-PE (561946, BD, USA), anti-NKG2D-APC (130-099-216, Miltenyi Biotec, Germany), anti-CD27-PE (560985, BD, USA), and anti-CD57-APC (560845, BD, USA) antibodies. To detect the infiltration of CD8 or NK cells in the tumor mass, tumors were removed and crushed into single cell suspension. Then cells were stained with mouse anti-CD8-PErCp (46-0083-80, eBioscience, USA) or anti-NK1.1-FITC (553164, BD, USA) antibodies. To confirm the depletion of CD8 or NK cells, cells were isolated from peripheral blood and stained with anti-CD8-PErCp (46-0083-80) or anti-NK1.1-PerCp antibodies (45-5941-82) (all from eBioscience, USA). The staining was performed on ice for 30 min. Samples were acquired on the FACS Calibur (BD, USA) and data was analyzed using FlowJo software (Version 8.5.3, Tree Star Inc., USA).
+ Open protocol
+ Expand
2

Evaluating Pluripotent Stem Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols
The viability of disaggregated primed and naive hESCs and hiPSCs was analyzed with a Life/Death Fixable kit (Invitrogen, Waltham, MA, USA) in a FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA). Cells were stained with anti-CD24 PE (BD Biosciences, clone ML5) and anti-CD57 APC (BD Bioscience, clone NK-1) primed markers with anti-CD75 FITC (BD Biosciences, clone LN1) and anti-CD130 BV421 (BD Biosciences, clone AM64) naive markers and anti-CD90 PE-Cy7 (BD Biosciences, clone 5E10) stemness marker. Approximately 30,000–50,000 events were acquired for analysis. Populations were analyzed using FlowJo v.X.0.7 (TreeStar Inc., Ashland, OR, USA). See Supplementary Table S1.
+ Open protocol
+ Expand
3

Multicolor Flow Cytometry Panels

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following flow cytometry antibodies were purchased from BD Biosciences (San Jose, CA): anti-CD3-PE Cy7, anti-CD4-Alexa488, anti-CD8-PacBlu, anti-CD28-PE, anti-CD57-APC, anti-CD45RO-Alexa 700, anti-HLA-DR-APC, anti-CD14-PacBlu, anti-CD11a-FITC, anti-CD16-PE-Cy7, anti-CD163-PE, anti-CD62L-APC, and anti-CD86-Alexa 700. Two multi-color panels were used for T cells, and two panels were used for monocytes. Data were collected using a BD LSRII flow cytometer and analyzed with FCS Express software (DeNovo Software, Los Angeles, CA).
+ Open protocol
+ Expand
4

Phenotypic Characterization of T-Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Hypaque (GE Healthcare, Sweden) and analyzed by flow cytometry. PBMCs were stained with fluorochrome-conjugated monoclonal antibodies against surface antigens for 30 min at 4 °C. The antibodies used included anti-CD3-PE-Cy7, anti-CD4-Horizon V500, anti-CD8-APC-Cy7, anti-CD31-FITC, anti-CXCR4-PerCP-Cy5.5, and anti-CD28-APC-H7 (all from BD Biosciences, San Jose, California, USA). Phenotypic characterization of CD28null-Tang and CD28+-Tang subsets was performed by extracellular staining with anti-CD57-APC, anti-CD27-APC, anti-CCR7-APC, or antihTERT-APC or the corresponding isotype controls (all from BD Biosciences). Multicolor flow cytometry was performed using an CytoFlex S (Beckman Coulter), and FlowJo V10 software (Treestar, San Carlos, California, USA) was used to analyze the data.
+ Open protocol
+ Expand
5

Isolation and Characterization of CMV-Specific CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
PE-conjugated HLA-A2 tetramers refolded around the CMV pp65495-503 epitope NLVPMVATV (NLV) were generated as described previously48 (link),49 (link) and used at a final concentration of 10 μg/mL. Directly conjugated mAbs were obtained from commercial suppliers: (i) anti-CD3-APC-H7, anti-CD8-BV786, anti-CD14-BV510, anti-CD19-BV510, anti-CD45-RA-PerCP-Cy5.5, anti-CD57-APC, anti-CD127-BV421, anti-CD160-PerCP-Cy5.5, anti-CCR7-PE-Cy7, anti-CTLA-4-PE-Cy7, anti-BTLA-APC, anti-2B4-FITC, anti-2B4-PE, and anti-Tim-3-AF700 (BD Biosciences); (ii) anti-CD27-BV605 and anti-PD-1-PE/Dazzle 594 (BioLegend); and (iii) a panel of anti-TCR-Vβ-FITC and anti-TCR-Vβ-PE mAbs (Beckman Coulter). The acute effects of dasatinib administration were monitored using an IOTest Beta Mark TCR Repertoire Kit (BD Biosciences). Non-viable cells were excluded from the analysis using LIVE/DEAD Fixable Aqua (Life Technologies). Data were acquired using a Fortessa X-20 flow cytometer (BD Biosciences) and analyzed with FlowJo software version 10.0.7 (Tree Star). Viable CD3+ CD8+ TCR-Vβ+ cells were sorted using an InfluxTM Cell Sorter (BD Biosciences).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!